DURAGESIC-75
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-75 is a transdermal extended-release film formulation approved in 1990 by Johnson & Johnson. The generic name and mechanism of action are not publicly disclosed in this dataset, but the transdermal delivery system suggests chronic pain management. This is a mature product approaching loss of exclusivity.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand team is likely focused on lifecycle extension and market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURAGESIC-75 offers limited career growth opportunities given the product's LOE-approaching status and zero linked job openings. Roles tend to focus on managing decline, defending market share, and preparing for generic transition rather than launching or scaling a franchise.
Brand ManagerMedical Science Liaison
Worked on DURAGESIC-75 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.